Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | FABP4 | P15090 | 2/20 | 0.37 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17029029 | 1.00 | NR1I2 (0.44) | NR1I2CYP3A4FABP4PSIP1 | |
| SCHEMBL17039243 | 1.00 | NR1I2 (0.44) | NR1I2CYP3A4FABP4PSIP1 | |
| SCHEMBL17039253 | 0.94 | NR1I2 (0.39) | NR1I2CYP3A4FABP4 | |
| SCHEMBL18364984 | 0.94 | NR1I2 (0.39) | NR1I2CYP3A4FABP4 | |
| SCHEMBL17029056 | 0.92 | NR1I2 (0.42) | NR1I2CYP3A4FABP4PSIP1 | |
| SCHEMBL17029028 | 0.92 | NR1I2 (0.42) | NR1I2CYP3A4FABP4PSIP1 | |
| SCHEMBL17029058 | 0.91 | NR1I2 (0.44) | NR1I2CYP3A4FABP4PSIP1 | |
| SCHEMBL17029018 | 0.89 | NR1I2 (0.40) | NR1I2CYP3A4FABP4PSIP1 | |
| SCHEMBL20344817 | 0.86 | NR1I2 (0.36) | NR1I2CYP3A4FABP4 | |
| SCHEMBL18364988 | 0.86 | NR1I2 (0.36) | NR1I2CYP3A4FABP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9938271-B2 | Inhibitors of human immunodeficiency virus replication | VIIV Healthcare UK (No.5) Limited (GB) | 2018-04-10 | — | — | US | disclosed |
| US-9938271-B2 | Inhibitors of human immunodeficiency virus replication | VIIV Healthcare UK (No.5) Limited (GB) | 2018-04-10 | — | — | US | disclosed |
| US-20170008887-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BRISTOL-MYERS SQUIBB COMPANY | 2017-01-12 | — | — | US | disclosed |
| US-20170008887-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BRISTOL-MYERS SQUIBB COMPANY | 2017-01-12 | — | — | US | disclosed |
| EP-3107913-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV HEALTHCARE (NO.5) LIMITED (GB) | 2016-12-28 | — | — | EP | disclosed |
| WO-2015126765-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-08-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170008887-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | EIF2AK2, RTF2, MAVS | NR1I2 3085/4885CYP3A4 1719/4885FABP4 4663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.